Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.
Also called NCT03066830
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 507 participants
- Sponsor
- Registry
-
NCT03066830 -
2016-002826-35
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Estonia, Hungary, Poland, Romania, Slovakia, South Korea, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03066830. Randomized; double masking; primary purpose treatment. Start 2017-02-24 (actual); primary completion 2019-04-17 (actual). Results posted on 2021-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sotagliflozin (SAR439954)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulfonylurea
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03066830- Content hash
c07f8e42b6138b6044a2a4667998f57fcdb889d9ef76e6c0c7e7d1a856582240